Adimmune Corporation (TPE:4142)
Taiwan
· Delayed Price · Currency is TWD 17.55
+0.05 (0.29%)
Jun 6, 2025, 1:30 PM CST
Adimmune Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,585 | 1,557 | 1,785 | 2,252 | 1,794 | 1,869 | Upgrade
|
| Revenue Growth (YoY) | -4.46% | -12.78% | -20.72% | 25.52% | -4.03% | 43.81% | Upgrade
|
| Cost of Revenue | 1,188 | 1,109 | 1,374 | 1,361 | 1,177 | 1,246 | Upgrade
|
| Gross Profit | 397.09 | 448.06 | 410.94 | 891.08 | 616.86 | 623.06 | Upgrade
|
| Selling, General & Admin | 464.8 | 455.11 | 442.87 | 446.11 | 349.67 | 311.19 | Upgrade
|
| Research & Development | 300.89 | 292.05 | 296.93 | 346.42 | 321.28 | 337.68 | Upgrade
|
| Operating Expenses | 765.55 | 747.01 | 1,134 | 797.52 | 670.95 | 648.88 | Upgrade
|
| Operating Income | -368.46 | -298.95 | -722.75 | 93.57 | -54.09 | -25.81 | Upgrade
|
| Interest Expense | -31.91 | -36.49 | -33.43 | -22.59 | -14.69 | -22.16 | Upgrade
|
| Interest & Investment Income | 23.78 | 22.01 | 26.2 | 14.89 | 12.58 | 11.99 | Upgrade
|
| Currency Exchange Gain (Loss) | 24.23 | 23.58 | -31.38 | 52.62 | 4.28 | -15.27 | Upgrade
|
| Other Non Operating Income (Expenses) | -38.83 | -46.67 | -8.85 | 17.72 | 8.32 | 28.01 | Upgrade
|
| EBT Excluding Unusual Items | -391.18 | -336.51 | -770.21 | 156.21 | -43.6 | -23.26 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 1.44 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.02 | 0.02 | -0.04 | 0.01 | 0.01 | 0.16 | Upgrade
|
| Legal Settlements | - | - | - | - | -4.39 | 1,159 | Upgrade
|
| Other Unusual Items | - | 0 | 0.26 | - | 62.27 | 59.63 | Upgrade
|
| Pretax Income | -391.16 | -336.49 | -769.98 | 156.22 | 14.29 | 1,197 | Upgrade
|
| Income Tax Expense | - | - | - | 10 | - | - | Upgrade
|
| Earnings From Continuing Operations | -391.16 | -336.49 | -769.98 | 146.22 | 14.29 | 1,197 | Upgrade
|
| Minority Interest in Earnings | 109.13 | 93.74 | 130.09 | 144.76 | 28.78 | 43.98 | Upgrade
|
| Net Income | -282.03 | -242.75 | -639.89 | 290.98 | 43.07 | 1,241 | Upgrade
|
| Net Income to Common | -282.03 | -242.75 | -639.89 | 290.98 | 43.07 | 1,241 | Upgrade
|
| Net Income Growth | - | - | - | 575.65% | -96.53% | - | Upgrade
|
| Shares Outstanding (Basic) | 422 | 422 | 422 | 427 | 430 | 409 | Upgrade
|
| Shares Outstanding (Diluted) | 422 | 422 | 422 | 428 | 430 | 410 | Upgrade
|
| Shares Change (YoY) | - | - | -1.44% | -0.45% | 4.77% | 32.11% | Upgrade
|
| EPS (Basic) | -0.67 | -0.58 | -1.52 | 0.68 | 0.10 | 3.03 | Upgrade
|
| EPS (Diluted) | -0.67 | -0.58 | -1.52 | 0.68 | 0.10 | 3.03 | Upgrade
|
| EPS Growth | - | - | - | 580.00% | -96.70% | - | Upgrade
|
| Free Cash Flow | -509.84 | 437.34 | -1,270 | -711.4 | -1,325 | 1,785 | Upgrade
|
| Free Cash Flow Per Share | -1.21 | 1.04 | -3.01 | -1.66 | -3.08 | 4.35 | Upgrade
|
| Dividend Per Share | - | - | - | - | - | 0.500 | Upgrade
|
| Gross Margin | 25.05% | 28.78% | 23.02% | 39.57% | 34.39% | 33.33% | Upgrade
|
| Operating Margin | -23.24% | -19.20% | -40.49% | 4.16% | -3.02% | -1.38% | Upgrade
|
| Profit Margin | -17.79% | -15.59% | -35.85% | 12.92% | 2.40% | 66.41% | Upgrade
|
| Free Cash Flow Margin | -32.16% | 28.09% | -71.15% | -31.60% | -73.84% | 95.48% | Upgrade
|
| EBITDA | -188.79 | -116.2 | -528.03 | 326.68 | 150.76 | 181.27 | Upgrade
|
| EBITDA Margin | -11.91% | -7.46% | -29.58% | 14.51% | 8.40% | 9.70% | Upgrade
|
| D&A For EBITDA | 179.67 | 182.75 | 194.72 | 233.12 | 204.85 | 207.08 | Upgrade
|
| EBIT | -368.46 | -298.95 | -722.75 | 93.57 | -54.09 | -25.81 | Upgrade
|
| EBIT Margin | -23.24% | -19.20% | -40.49% | 4.16% | -3.02% | -1.38% | Upgrade
|
| Effective Tax Rate | - | - | - | 6.40% | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.